DK0504363T3 - Rensede IgG antistoffer - Google Patents

Rensede IgG antistoffer

Info

Publication number
DK0504363T3
DK0504363T3 DK91917891T DK91917891T DK0504363T3 DK 0504363 T3 DK0504363 T3 DK 0504363T3 DK 91917891 T DK91917891 T DK 91917891T DK 91917891 T DK91917891 T DK 91917891T DK 0504363 T3 DK0504363 T3 DK 0504363T3
Authority
DK
Denmark
Prior art keywords
antibody
column
prepn
cdw52
purified
Prior art date
Application number
DK91917891T
Other languages
English (en)
Other versions
DK0504363T4 (da
Inventor
Geoffrey Langley Court Allen
Paul Ian Nicholas Ramage
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10683866&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0504363(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Found filed Critical Wellcome Found
Application granted granted Critical
Publication of DK0504363T3 publication Critical patent/DK0504363T3/da
Publication of DK0504363T4 publication Critical patent/DK0504363T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK91917891T 1990-10-17 1991-10-17 Rensede IgG antistoffer DK0504363T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909022547A GB9022547D0 (en) 1990-10-17 1990-10-17 Purified immunoglobulin
PCT/GB1991/001816 WO1992007084A1 (en) 1990-10-17 1991-10-17 Purified cdw52-specific antibodies

Publications (2)

Publication Number Publication Date
DK0504363T3 true DK0504363T3 (da) 1998-09-21
DK0504363T4 DK0504363T4 (da) 2007-05-29

Family

ID=10683866

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91917891T DK0504363T4 (da) 1990-10-17 1991-10-17 Rensede IgG antistoffer

Country Status (29)

Country Link
US (1) US5644036A (da)
EP (1) EP0504363B2 (da)
JP (1) JP2638680B2 (da)
KR (2) KR960015399B1 (da)
AT (2) ATA900791A (da)
AU (3) AU658926B2 (da)
BE (1) BE1004226A5 (da)
BR (1) BR1100358A (da)
CA (1) CA2069481C (da)
CH (2) CH681455A5 (da)
DE (1) DE69128774T3 (da)
DK (1) DK0504363T4 (da)
ES (2) ES2112865T5 (da)
FI (2) FI110003B (da)
FR (2) FR2668164A1 (da)
GB (2) GB9022547D0 (da)
GR (3) GR910100425A (da)
HU (1) HUT64601A (da)
IE (1) IE913560A1 (da)
IL (3) IL99761A0 (da)
IT (1) IT1250064B (da)
LU (1) LU88122A1 (da)
MX (1) MX9203794A (da)
MY (2) MY136210A (da)
NZ (2) NZ240247A (da)
PT (2) PT99248B (da)
TW (1) TW283710B (da)
WO (1) WO1992007084A1 (da)
ZA (2) ZA918259B (da)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
KR100264218B1 (ko) * 1991-10-15 2000-08-16 그레이엄 브레레톤 관절의 T-세포 매개 염증의 치료용 CDw52-특이 항체
GB9125768D0 (en) * 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
GB9300501D0 (en) * 1993-01-09 1993-03-03 Wellcome Found Purification of immunoglobulin
EP0841942B2 (fr) † 1995-08-01 2007-12-12 Sanofi Pasteur Procede de production industrielle d'un vaccin contre l'encephalite japonaise et vaccin obtenu
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
DK0929578T3 (da) * 1996-02-09 2003-08-25 Abbott Lab Bermuda Ltd Humane antistoffer, der binder human TNFalfa
GB9603256D0 (en) * 1996-02-16 1996-04-17 Wellcome Found Antibodies
US20030023043A1 (en) * 2000-03-02 2003-01-30 Kazuhisa Uchida Method of separating and purifying protein
EP3088412B1 (en) 2001-03-09 2021-05-05 Chugai Seiyaku Kabushiki Kaisha Protein purification method
DE60213248T2 (de) * 2001-06-05 2006-11-30 Genetics Institute, LLC, Cambridge Verfahren zur reinigung hochanionischer proteine
GB0220894D0 (en) * 2002-09-09 2002-10-16 Millipore Uk Ltd Method of separation
ES2558303T3 (es) 2002-09-11 2016-02-03 Chugai Seiyaku Kabushiki Kaisha Método de purificación de proteínas
WO2004035618A2 (en) 2002-10-15 2004-04-29 Intercell Ag Nucleic acids coding for adhesion factor of group b streptococcus, adhesion factors of group b streptococcus and further uses thereof
GB0304576D0 (en) * 2003-02-28 2003-04-02 Lonza Biologics Plc Protein a chromatography
JP2007515492A (ja) * 2003-12-22 2007-06-14 ジェンザイム コーポレイション 糖尿病の抗ｃｄ５２抗体治療法
AU2006223180B2 (en) * 2005-03-11 2011-11-24 Wyeth Llc A method of weak partitioning chromatography
ES2892925T3 (es) 2006-03-31 2022-02-07 Chugai Pharmaceutical Co Ltd Métodos para controlar la farmacocinética en sangre de anticuerpos
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
CA2761885A1 (en) 2009-05-13 2010-11-18 Genzyme Corporation Methods and compositions for treating lupus
EP2998405B1 (en) 2009-05-13 2019-12-11 Genzyme Corporation Anti-human cd52 immunoglobulins
US20130178608A1 (en) * 2009-12-29 2013-07-11 Samir Kulkarni Protein purification by ion exchange
EP3266793A1 (en) 2010-06-21 2018-01-10 Kyowa Hakko Kirin Co., Ltd. Method for purifying protein using amino acid
RU2467783C2 (ru) * 2010-07-30 2012-11-27 Закрытое акционерное общество "БиоХимМак СТ" Способ хроматографического выделения иммуноглобулина
TWI812066B (zh) 2010-11-30 2023-08-11 日商中外製藥股份有限公司 具有鈣依存性的抗原結合能力之抗體
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
GB201109238D0 (en) * 2011-06-01 2011-07-13 Antitope Ltd Antibodies
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US9650411B2 (en) 2012-08-07 2017-05-16 Kyowa Hakko Kirin Co., Ltd. Method of purifying protein
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
HK1211981A1 (en) 2012-09-02 2016-06-03 Abbvie Inc. Methods to control protein heterogeneity
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
AR095199A1 (es) 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
AU2013203043B2 (en) 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
BR112016014824A2 (pt) 2013-12-27 2017-09-19 Chugai Pharmaceutical Co Ltd Método para purificar anticorpo que tem ponto isoelétrico baixo
KR101860280B1 (ko) 2014-12-19 2018-05-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
CN114773470A (zh) 2015-02-05 2022-07-22 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
WO2017022651A1 (ja) 2015-07-31 2017-02-09 中外製薬株式会社 アニオン性ポリマーによる抗体を含有する組成物の精製方法
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
US10688412B2 (en) 2016-07-25 2020-06-23 Cehpalon, Inc. Affinity chromatography wash buffer
TWI693940B (zh) 2016-08-05 2020-05-21 日商中外製藥股份有限公司 Ｉｌ-８相關疾病之治療用或預防用組成物
CN113646066B (zh) 2019-03-29 2024-05-31 旭化成医疗株式会社 蛋白质的纯化方法
US12383884B2 (en) 2019-04-08 2025-08-12 Asahi Kasei Medical Co., Ltd. Polyamide medium for purifying protein-containing solution and method for producing polyamide medium
JP7583411B2 (ja) 2019-04-10 2024-11-14 中外製薬株式会社 Ｆｃ領域改変抗体の精製方法
CN117241881A (zh) 2021-06-10 2023-12-15 三菱化学株式会社 合成吸附剂、抗体的纯化方法和抗体的制造方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118796A (en) * 1987-12-09 1992-06-02 Centocor, Incorporated Efficient large-scale purification of immunoglobulins and derivatives
WO1989007452A1 (en) * 1988-02-12 1989-08-24 Medical Research Council Improvements in or relating to antibodies

Also Published As

Publication number Publication date
FR2668164B1 (da) 1995-04-14
ES2112865T5 (es) 2007-09-16
EP0504363B1 (en) 1998-01-21
AU4521897A (en) 1998-02-12
GR3026588T3 (en) 1998-07-31
IL99761A0 (en) 1992-08-18
BE1004226A5 (fr) 1992-10-13
FI922380A0 (fi) 1992-05-25
MY136210A (en) 2008-08-29
GB9022547D0 (en) 1990-11-28
KR960015399B1 (ko) 1996-11-13
BR1100358A (pt) 2000-03-28
CH681455A5 (da) 1993-03-31
NZ240247A (en) 1994-03-25
MY119030A (en) 2005-03-31
KR920703108A (ko) 1992-12-17
IT1250064B (it) 1995-03-30
CA2069481C (en) 2003-07-29
ES2081742B1 (es) 1996-10-01
PT100988B (pt) 1999-08-31
GR910100425A (el) 1992-09-25
GB2253397A (en) 1992-09-09
JP2638680B2 (ja) 1997-08-06
TW283710B (da) 1996-08-21
ES2081742A1 (es) 1996-03-01
CA2069481A1 (en) 1992-04-18
AU658926B2 (en) 1995-05-04
AU649078B2 (en) 1994-05-12
ZA926191B (en) 1993-04-16
EP0504363B2 (en) 2007-02-07
AU7024294A (en) 1995-01-05
ITRM910788A0 (it) 1991-10-16
AU2532192A (en) 1993-02-11
DE69128774T2 (de) 1998-06-04
AU716402B2 (en) 2000-02-24
ATA900791A (de) 1996-06-15
PT100988A (pt) 1994-02-28
LU88122A1 (fr) 1993-03-15
MX9203794A (es) 1992-07-01
FI922380L (fi) 1992-05-25
FR2668164A1 (fr) 1992-04-24
FR2677997A1 (fr) 1992-12-24
DK0504363T4 (da) 2007-05-29
HUT64601A (en) 1994-01-28
AU8729491A (en) 1992-05-20
DE69128774T3 (de) 2007-08-16
IL102726A (en) 2002-08-14
GR920100471A (el) 1994-06-30
EP0504363A1 (en) 1992-09-23
FI922824A0 (fi) 1992-06-17
GB9209529D0 (en) 1992-07-01
HU9202000D0 (en) 1992-10-28
US5644036A (en) 1997-07-01
PT99248B (pt) 1999-04-30
PT99248A (pt) 1993-06-30
FI110002B (fi) 2002-11-15
JPH05504579A (ja) 1993-07-15
WO1992007084A1 (en) 1992-04-30
IL102726A0 (en) 1993-01-31
ZA918259B (en) 1993-04-16
ATE162552T1 (de) 1998-02-15
FI110003B (fi) 2002-11-15
ITRM910788A1 (it) 1993-04-16
CH681305A5 (da) 1993-02-26
KR100193314B1 (ko) 1999-06-15
NZ244114A (en) 1995-06-27
FI922824L (fi) 1992-06-17
DE69128774D1 (de) 1998-02-26
ES2112865T3 (es) 1998-04-16
IE913560A1 (en) 1992-04-22

Similar Documents

Publication Publication Date Title
DE69128774D1 (de) GEREINIGTE IgG ANTIKÖRPER
EP0185034A4 (da)
AU7067287A (en) Method and apparatus for separating proteins
Dimitrijevic et al. Purification and characterization of an estrogen-binding peroxidase from human fetuses
ATE118782T1 (de) Reinigungsverfahren für interferon.
DENG PURIFICATION OF HUMAN INTERFERON-? BY ANTIBODY AFFINITY CHROMATOGRAPY
IT1237997B (it) Assorbenti tiofilici